Advertisement

Human Immunodeficiency Virus Treatment and Prevention for Pregnant and Postpartum Women in Global Settings

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Obstetrics and Gynecology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kourtis A.P.
        • Ellington S.
        • Pazol K.
        • et al.
        Complications of cesarean deliveries among HIV-infected women in the United States.
        AIDS. 2014; 28: 2609-2618https://doi.org/10.1097/QAD.0000000000000474
        • UNAIDS
        Fast-Track - Ending the AIDS Epidemic by 2030.
        UNAIDS. 2014; (Accessed April 4, 2020)
        • Teasdale C.A.
        • Marais B.J.
        • Abrams E.J.
        HIV: prevention of mother-to-child transmission.
        BMJ Clin Evid. 2011; 2011: 0909
        • Fowler M.G.
        • Qin M.
        • Fiscus S.A.
        • et al.
        Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.
        N Engl J Med. 2016; 375: 1726-1737
        • World Health Organization
        World Health Organization HIV/AIDS.
        WHO. 2018; (Accessed March 1, 2022)
        • Cohen M.S.
        • Chen Y.Q.
        • McCauley M.
        • et al.
        Prevention of HIV-1 Infection with Early Antiretroviral Therapy | NEJM.
        (Accessed April 15, 2022)
        • Hoffman R.M.
        • Angelidou K.N.
        • Brummel S.S.
        • et al.
        Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial.
        HIV Clin Trials. 2018; 19: 209-224
      1. UNAIDS DATA.
        (Accessed April 21, 2022)
        • Graybill L.A.
        • Kasaro M.
        • Freeborn K.
        • et al.
        Incident HIV among pregnant and breast-feeding women in sub-Saharan Africa: a systematic review and meta-analysis.
        AIDS. 2020; 34: 761-776https://doi.org/10.1097/QAD.0000000000002487
        • Drake A.L.
        • Wagner A.
        • Richardson B.
        • et al.
        Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis.
        Plos Med. 2014; (Mofenson LM, ed): e1001608https://doi.org/10.1371/journal.pmed.1001608
        • Abbai N.S.
        • Wand H.
        • Ramjee G.
        Biological factors that place women at risk for HIV: evidence from a large-scale clinical trial in Durban.
        BMC Women’s Health. 2016; 16: 19https://doi.org/10.1186/s12905-016-0295-5
        • Fonner V.A.
        • Dalglish S.L.
        • Kennedy C.E.
        • et al.
        Effectiveness and safety of oral HIV preexposure prophylaxis for all populations.
        AIDS. 2016; 30: 1973-1983https://doi.org/10.1097/QAD.0000000000001145
        • Pintye J.
        • Davey D.L.J.
        • Wagner A.D.
        • et al.
        Defining gaps in pre-exposure prophylaxis delivery for pregnant and post-partum women in high-burden settings using an implementation science framework - PubMed.
        (Available at:) (Accessed April 15, 2022)
        • Joseph Davey D.L.
        • Bekker L.G.
        • Gorbach P.M.
        • et al.
        Delivering preexposure prophylaxis to pregnant and breastfeeding women in Sub-Saharan Africa: the implementation science frontier.
        AIDS. 2017; 31: 2193-2197https://doi.org/10.1097/QAD.0000000000001604
        • Chi B.H.
        • Rosenberg N.E.
        • Mweemba O.
        • et al.
        Involving both parents in HIV prevention during pregnancy and breastfeeding.
        Bull World Health Organ. 2018; 96: 69-71https://doi.org/10.2471/BLT.17.200139
        • Stringer E.M.
        • Chi B.H.
        • Chintu N.
        • et al.
        Monitoring effectiveness of programmes to prevent mother-to-child HIV transmission in lower-income countries.
        Bull World Health Organ. 2008; 86: 57-62https://doi.org/10.2471/BLT.07.043117
        • Hamilton E.
        • Bossiky B.
        • Ditekemena J.
        • et al.
        Using the PMTCT Cascade to Accelerate Achievement of the Global Plan Goals - PubMed.
        (Available at:) (Accessed April 15, 2022)
        • McNairy M.L.
        • Lamb M.R.
        • Abrams E.J.
        • et al.
        Use of a Comprehensive HIV Care Cascade for Evaluating HIV Program Performance: Findings From 4 Sub-Saharan African Countries.
        J Acquir Immune Defic Syndr. 2015; 70: e44-e51https://doi.org/10.1097/QAI.0000000000000745
        • Awopegba O.E.
        • Kalu A.
        • Ahinkorah B.O.
        • et al.
        Prenatal care coverage and correlates of HIV testing in sub-Saharan Africa: insight from demographic and health surveys of 16 countries.
        PLoS One. 2020; (Kalk EK, ed): e0242001https://doi.org/10.1371/journal.pone.0242001
        • Powers K.A.
        • Orroth K.
        • Rosenberg N.E.
        • et al.
        A mathematical modeling analysis of combination HIV prevention in antenatal clinics. Presented at: conference on Retroviruses and Opportunistic Infections2019.
        2019 (Paper presented at: 2019 Conference on Retroviruses and Opportunistic Infections2019)
        • Myers J.E.
        • Braunstein S.L.
        • Xia Q.
        • et al.
        Redefining Prevention and Care: A Status-Neutral Approach to HIV.
        Open Forum Infect Dis. 2018; 5: ofy097https://doi.org/10.1093/ofid/ofy097
      2. Magiorkinis G, Angelis K, Mamais I, et al. The global spread of HIV-1 subtype B epidemic -. Infect Genet Evol. doi:10.1016/j.meegid.2016.05.041.

        • Chilaka V.N.
        • Konje J.C.
        HIV in pregnancy – An update.
        Eur J Obstet Gynecol Reprod Biol. 2021; 256: 484-491https://doi.org/10.1016/j.ejogrb.2020.11.034
        • Brocklehurst P.
        • French R.
        The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis.
        Br J Obstet Gynaecol. 1998; 105: 836-848https://doi.org/10.1111/j.1471-0528.1998.tb10227.x
        • Twabi H.S.
        • Manda S.O.
        • Small D.S.
        Assessing the effects of maternal HIV infection on pregnancy outcomes using cross-sectional data in Malawi.
        BMC Public Health. 2020; 20: 974https://doi.org/10.1186/s12889-020-09046-0
        • Kim M.H.
        • Ahmed S.
        • Hosseinipour M.C.
        • et al.
        The Impact of Option B+ on the Antenatal PMTCT Cascade in Lilongwe, Malawi.
        J Acquir Immune Defic Syndr. 2015; 68: 7
        • Miro J.M.
        • Manzardo C.
        • Mussini C.
        • et al.
        Survival Outcomes and Effect of Early vs. Deferred cART Among HIV-Infected Patients Diagnosed at the Time of an AIDS-Defining Event: A Cohort Analysis - PMC.
        (Available at:) (Accessed March 17, 2022)
        • Becquet R.
        • Bland R.
        • Ekouevi D.K.
        • et al.
        Universal antiretroviral therapy among pregnant and postpartum HIV-infected women would improve maternal health and decrease postnatal HIV transmission.
        AIDS. 2010; 24: 1239-1241https://doi.org/10.1097/QAD.0b013e328338b791
        • Cohen M.S.
        • Chen Y.Q.
        • McCauley M.
        • et al.
        Antiretroviral Therapy for the Prevention of HIV-1 Transmission | NEJM.
        (Available at:) (Accessed March 1, 2022)
        • World Health Organization
        Prevention of mother-to-child transmission - Estimates by WHO region. WHO.
        (Available at:) (Accessed February 27, 2022)
        • The INSIGHT START Study Group
        Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.
        N Engl J Med. 2015; 373: 795-807https://doi.org/10.1056/NEJMoa1506816
        • Bispo S.
        • Chikhungu L.
        • Rollins N.
        • et al.
        Postnatal HIV transmission in breastfed infants of HIV-infected women on ART: a systematic review and meta-analysis.
        J Int AIDS Soc. 2017; 20: 21251https://doi.org/10.7448/IAS.20.1.21251
        • Choudhary Madhu Chhanda
        Antiretroviral Therapy (ART) in Pregnant Women With HIV Infection: Overview of HIV Antiretroviral Therapy (ART) in Pregnancy, Clinical Data on HIV Antiretroviral Therapy (ART) in Pregnancy, Factors for HIV Antiretroviral Therapy (ART) Selection in Pregnancy.
        (Available at:) (Accessed March 15, 2022)
        • Goetghebuer T.
        • Smolen K.K.
        • Adler C.
        • et al.
        Initiation of Antiretroviral Therapy Before Pregnancy Reduces the Risk of Infection-related Hospitalization in Human Immunodeficiency Virus–exposed Uninfected Infants Born in a High-income Country.
        Clin Infect Dis. 2019; 68: 1193-1203https://doi.org/10.1093/cid/ciy673
        • Brennan A.T.
        • Bonawitz R.
        • Gill C.J.
        • et al.
        A meta-analysis assessing all-cause mortality in HIV-exposed uninfected compared with HIV-unexposed uninfected infants and children.
        AIDS. 2016; 30: 2351-2360https://doi.org/10.1097/QAD.0000000000001211
        • Schouten E.J.
        • Jahn A.
        • Midiani D.
        • et al.
        Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach.
        Lancet. 2011; 378: 282-284https://doi.org/10.1016/S0140-6736(10)62303-3
        • World Health Organization
        WHO. Programmatic update guidelines use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Executive summary.
        2012 (Available at:)
      3. Stover J, Bollinger L, Izazola JA, et al. What is required to end the AIDS epidemic as a public health threat by 2030? The cost and impact of the fast-track approach. Available at: https://doi.org/10.1371/journal.pone.0213970. Accessed April 13, 2022.

        • CDC
        Impact of an innovative approach to prevent mother-to-child transmission of HIV — Malawi.
        2011 (Available at:) (Accessed March 17, 2022)
        • World Health Organization
        Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach.
        World Health Organization, 2016 (Available at:) (Accessed February 25, 2022)
        • Astawesegn F.H.
        • Stulz V.
        • Conroy E.
        • et al.
        Trends and effects of antiretroviral therapy coverage during pregnancy on mother-to-child transmission of HIV in Sub-Saharan Africa. Evidence from panel data analysis.
        BMC Infect Dis. 2022; 22: 134https://doi.org/10.1186/s12879-022-07119-6
        • Uthman O.A.
        • Nachega J.B.
        • Anderson J.
        • et al.
        Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis.
        Lancet HIV. 2017; 4: e21-e30https://doi.org/10.1016/S2352-3018(16)30195-3
        • World Health Organization
        Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach.
        (Available at:)
        • Recommendations N.I.H.
        for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States.
        (Available at:) (Accessed February 26, 2022)
        • Sheth A.N.
        • Rolle C.P.
        • Gandhi M.
        HIV pre-exposure prophylaxis for women.
        J Virus Eradication. 2016; 2: 149-155https://doi.org/10.1016/S2055-6640(20)30458-1
        • Chersich M.F.
        • Urban M.F.
        • Venter F.W.
        • et al.
        Efavirenz use during pregnancy and for women of child-bearing potential.
        AIDS Res Ther. 2006; 3: 11https://doi.org/10.1186/1742-6405-3-11
        • Zash R.
        • Souda S.
        • Chen J.Y.
        • et al.
        Reassuring Birth Outcomes With Tenofovir/Emtricitabine/Efavirenz Used for Prevention of Mother-to-Child Transmission of HIV in Botswana.
        JAIDS J Acquired Immune Deficiency Syndromes. 2016; 71: 428-436https://doi.org/10.1097/QAI.0000000000000847
        • Ford N.
        • Calmy A.
        • Mofenson L.
        Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.
        AIDS. 2011; 25: 2301-2304https://doi.org/10.1097/QAD.0b013e32834cdb71
        • Ford N.
        • Mofenson L.
        • Shubber Z.
        • et al.
        Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.
        AIDS. 2014; 28: S123-S131https://doi.org/10.1097/QAD.0000000000000231
        • World Health Organization
        WHO recommends dolutegravir as preferred HIV treatment option in all populations.
        (Available at:) (Accessed March 19, 2022)
        • Zash R.
        • Holmes L.
        • Diseko M.
        • et al.
        Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.
        N Engl J Med. 2019; 381: 827-840https://doi.org/10.1056/NEJMoa1905230
        • Lyerly A.D.
        • Beigi R.
        • Bekker L.G.
        • et al.
        Ending the evidence gap for pregnancy, HIV and co-infections: ethics guidance from the PHASES project.
        J Int AIDS Soc. 2021; 24: e25846https://doi.org/10.1002/jia2.25846
        • American College of Obstetricians and Gynecologists (ACOG)
        Labor and Delivery Management of Women With Human Immunodeficiency Virus Infection.
        (Available at:) (Accessed June 28, 2022)
        • Andiman W.
        • Bryson Y.
        • de Martino M.
        • Fowler M.
        • Harris D.
        • et al.
        The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1--a meta-analysis of 15 prospective cohort studies.
        (Available at:) (Accessed June 28, 2022)
        • João E.C.
        • Morrison R.L.
        • Shapiro D.E.
        • et al.
        Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
        Lancet HIV. 2020; 7: e322-e331https://doi.org/10.1016/S2352-3018(20)30038-2
        • World Health Organization. World Health Organization
        WHO technical brief: preventing HIV during pregnancy and breastfeeding in the context of pre-exposure prophylaxis (PrEP).
        World Health Organization, Geneva2017 (Available at:) (Accessed April 8, 2020)
        • Thomson K.A.
        • Hughes J.
        • Baeten J.M.
        • et al.
        Increased Risk of HIV Acquisition Among Women Throughout Pregnancy and During the Postpartum Period: A Prospective Per-Coital-Act Analysis Among Women With HIV-Infected Partners.
        J Infect Dis. 2018; 218: 16-25https://doi.org/10.1093/infdis/jiy113
        • Mushamiri I.
        • Adudans M.
        • Apat D.
        • et al.
        Optimizing PMTCT efforts by repeat HIV testing during antenatal and perinatal care in resource-limited settings: A longitudinal assessment of HIV seroconversion.
        PLOS ONE. 2020; 15: e0233396https://doi.org/10.1371/journal.pone.0233396
      4. UNAIDS DATA 2021.
        (Available at:) (Accessed April 16, 2022)
      5. Global HIV & AIDS statistics — Fact sheet.
        (Available at:) (Accessed April 16, 2022)
        • Mofenson L.
        • Baggaley R.
        • Mameletzis I.
        Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding.
        Aids. 2017; 31: 213-232https://doi.org/10.1097/QAD.0000000000001313
        • Grant R.M.
        • Lama J.R.
        • Anderson P.L.
        • et al.
        Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men.
        N Engl J Med. 2010; 363: 2587-2599https://doi.org/10.1056/NEJMoa1011205
        • Stranix-Chibanda L.
        • Anderson P.L.
        • Kacanek D.
        • et al.
        • IMPAACT
        Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa - PubMed.
        (Available at:) (Accessed April 15, 2022)
        • Davies N.
        • Heffron R.
        Global and national guidance for the use of pre-exposure prophylaxis during peri-conception, pregnancy and breastfeeding.
        Sex Health. 2018; 15: 501https://doi.org/10.1071/SH18067
        • Hanscom B.
        • Janes H.E.
        • Guarino P.D.
        • et al.
        Preventing HIV-1 Infection in Women using Oral Pre-Exposure Prophylaxis: A Meta-analysis of Current Evidence.
        J Acquir Immune Defic Syndr. 2016; 73: 606-608https://doi.org/10.1097/QAI.0000000000001160
        • Kinuthia J.
        • Pintye J.
        • Abuna F.
        • et al.
        Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme.
        Lancet HIV. 2020; 7: e38-e48https://doi.org/10.1016/S2352-3018(19)30335-2
        • Joseph Davey D.L.
        • Mvududu R.
        • Mashele N.
        • et al.
        Early pre-exposure prophylaxis (PrEP) initiation and continuation among pregnant and postpartum women in antenatal care in Cape Town, South Africa.
        J Int AIDS Soc. 2022; 25: e25866https://doi.org/10.1002/jia2.25866
        • Baeten J.M.
        • Palanee-Phillips T.
        • Brown E.R.
        • et al.
        Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.
        New Engl J Med. 2016; 375: 2121-2132https://doi.org/10.1056/NEJMoa1506110
        • Nel A.
        • van Niekerk N.
        • Kapiga S.
        • et al.
        Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women - PubMed.
        (Accessed April 15, 2022)
        • Nel A.
        • van Niekerk N.
        • Van Baelen B.
        • et al.
        HIV incidence and adherence in DREAM: an open-label trial of dapivirine vaginal ring [Abstract #144LB]. Presented at: 2018; Conference on Retroviruses and Opportunistic Infections2018.
        (Available at:) (Accessed April 15, 2022)
        • Brown E.R.
        • Hendrix C.W.
        • van der Straten A.
        • et al.
        Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.
        J Int AIDS Soc. 2020; 23: e25634https://doi.org/10.1002/jia2.25634
      6. Where we are with the DELIVER and B-PROTECTED studies.
        (Available at:) (Accessed April 17, 2022)
      7. Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. Published online April 1, 2022. doi:10.1016/S0140-6736(22)00538-4.

        • Landovitz R.J.
        • Donnell D.
        • Clement M.E.
        • et al.
        Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.
        N Engl J Med. 2021; 385: 595-608https://doi.org/10.1056/NEJMoa2101016
      8. Commissioner O of the. FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention. FDA. Published December 20, 2021.
        (Available at:) (Accessed April 15, 2022)
        • Mayer K.H.
        • Molina J.M.
        • Thompson M.A.
        • et al.
        Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
        Lancet. 2020; 396: 239-254https://doi.org/10.1016/S0140-6736(20)31065-5
      9. HIV prevention options during pregnancy and breastfeeding – what’s in the pipeline?.
        (Available at:) (Accessed April 17, 2022)
        • Joseph Davey D.L.
        • Bekker L.G.
        • Bukusi E.A.
        • et al.
        Where are the pregnant and breastfeeding women in new pre-exposure prophylaxis trials? The imperative to overcome the evidence gap.
        Lancet HIV. 2022; 9: e214-e222https://doi.org/10.1016/S2352-3018(21)00280-0
        • Jones D.L.
        • Peltzer K.
        • Villar-Loubet O.
        • et al.
        Reducing the risk of HIV infection during pregnancy among South African women: a randomized controlled trial.
        AIDS Care. 2013; 25: 702-709https://doi.org/10.1080/09540121.2013.772280
        • Homsy J.
        • King R.
        • Bannink F.
        • et al.
        Primary HIV prevention in pregnant and lactating Ugandan women: A randomized trial.
        PLOS ONE. 2019; 14: e0212119https://doi.org/10.1371/journal.pone.0212119
        • Fatti G.
        • Shaikh N.
        • Jackson D.
        • et al.
        Low HIV incidence in pregnant and postpartum women receiving a community-based combination HIV prevention intervention in a high HIV incidence setting in South Africa.
        (Available at:) (Accessed April 15, 2022)
        • Saidi F.
        • Mutale W.
        • Freeborn K.
        • et al.
        Combination adherence strategy to support HIV antiretroviral therapy and pre-exposure prophylaxis adherence during pregnancy and breastfeeding: protocol for a pair of pilot randomised trials.
        BMJ Open. 2021; 11: e046032https://doi.org/10.1136/bmjopen-2020-046032
        • Hill L.M.
        • Saidi F.
        • Freeborn K.
        • et al.
        Tonse Pamodzi: Developing a combination strategy to support adherence to antiretroviral therapy and HIV pre-exposure prophylaxis during pregnancy and breastfeeding.
        (Available at:) (Accessed April 15, 2022)
        • Turner B.J.
        • McKee L.J.
        • Silverman N.S.
        • et al.
        Prenatal Care and Birth Outcomes of a Cohort of HIV-Infected Women.
        JAIDS J Acquired Immune Deficiency Syndromes. 1996; 12: 259-267
        • Cowdell I.
        • Beck K.
        • Portwood C.
        • et al.
        Adverse perinatal outcomes associated with protease inhibitor-based antiretroviral therapy in pregnant women living with HIV: A systematic review and meta-analysis.
        eClinicalMedicine. 2022; 0https://doi.org/10.1016/j.eclinm.2022.101368
        • Tukei V.J.
        • Hoffman H.J.
        • Greenberg L.
        • et al.
        Adverse Pregnancy Outcomes Among HIV-positive Women in the Era of Universal Antiretroviral Therapy Remain Elevated Compared With HIV-negative Women.
        Pediatr Infect Dis J. 2021; 40: 821-826https://doi.org/10.1097/INF.0000000000003174
      10. Perinatal outcomes in women living with HIV-1 and receiving antiretroviral therapy—a systematic review and meta-analysis - Shinar - 2022 - Acta Obstetricia et Gynecologica Scandinavica - Wiley Online Library.
        (Available at:) (Accessed April 20, 2022)
        • Moodley T.
        • Moodley D.
        • Sebitloane M.
        • et al.
        Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa.
        BMC Pregnancy Childbirth. 2016; 16: 35https://doi.org/10.1186/s12884-016-0821-3
        • Dadabhai S.
        • Gadama L.
        • Chamanga R.
        • et al.
        Pregnancy Outcomes in the Era of Universal Antiretroviral Treatment in Sub-Saharan Africa (POISE Study).
        JAIDS J Acquired Immune Deficiency Syndromes. 2019; 80: 7-14https://doi.org/10.1097/QAI.0000000000001875
        • Hoffman R.M.
        • Brummel S.S.
        • Britto P.
        • et al.
        Adverse Pregnancy Outcomes Among Women Who Conceive on Antiretroviral Therapy.
        Clin Infect Dis. 2019; 68: 273-279https://doi.org/10.1093/cid/ciy471
        • Stringer E.M.
        • Kendall M.A.
        • Lockman S.
        • et al.
        Pregnancy outcomes among HIV-infected women who conceived on antiretroviral therapy.
        PLoS ONE. 2018; (Law M, ed): e0199555https://doi.org/10.1371/journal.pone.0199555
        • Malaba T.R.
        • Phillips T.
        • Le Roux S.
        • et al.
        Antiretroviral therapy use during pregnancy and adverse birth outcomes in South African women.
        Int J Epidemiol. 2017; 46: 1678-1689https://doi.org/10.1093/ije/dyx136
        • Maswime S.
        • Pule C.
        • Bebell L.M.
        • et al.
        Stillbirth rate by maternal HIV serostatus and antiretroviral use in pregnancy in South Africa: An audit - PMC.
        (Available at:) (Accessed February 27, 2022)
        • Rempis E.M.
        • Schnack A.
        • Decker S.
        • et al.
        Option B+ for prevention of vertical HIV transmission has no influence on adverse birth outcomes in a cross-sectional cohort in Western Uganda.
        BMC Pregnancy Childbirth. 2017; 17: 82https://doi.org/10.1186/s12884-017-1263-2
        • Chagomerana M.B.
        • Miller W.C.
        • Pence B.W.
        • et al.
        PMTCT Option B+ Does Not Increase Preterm Birth Risk and May Prevent Extreme Prematurity: A Retrospective Cohort Study in Malawi.
        J Acquir Immune Defic Syndr. 2017; 74: 367-374https://doi.org/10.1097/qai.0000000000001253
        • Malaba T.R.
        • Newell M.L.
        • Myer L.
        • et al.
        Methodological Considerations for Preterm Birth Research.
        Front Glob Women’s Health. 2022; 2 (Available at:) (Accessed April 20, 2022)
        • Zash R.
        • Jacobson D.L.
        • Diseko M.
        • et al.
        Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy.
        JAMA Pediatr. 2017; 171https://doi.org/10.1001/jamapediatrics.2017.2222
        • Veroniki A.A.
        • Antony J.
        • Straus S.E.
        • et al.
        Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: systematic review and network meta-analysis including different study designs.
        PLoS ONE. 2018; (Kanters S, ed): e0198447https://doi.org/10.1371/journal.pone.0198447
        • Lockman S.
        • Brummel S.S.
        • Ziemba L.
        • et al.
        Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.
        The Lancet. 2021; 397: 1276-1292https://doi.org/10.1016/S0140-6736(21)00314-7
        • Dodd J.M.
        • Jones L.
        • Flenady V.
        • et al.
        Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth.
        Cochrane Database Syst Rev. 2013; 7: CD004947https://doi.org/10.1002/14651858.CD004947.pub3
        • Price J.T.
        • Vwalika B.
        • Freeman B.L.
        • et al.
        Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial.
        Lancet HIV. 2021; 8: e605-e613https://doi.org/10.1016/S2352-3018(21)00150-8
        • Mugo N.R.
        • Hong T.
        • Celum C.
        • et al.
        • Partners PrEP Study Team
        Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial - PubMed.
        (Available at:) (Accessed April 19, 2022)
        • Kinuthia J.
        • Pintye J.
        • Abuna F.
        • et al.
        PrEP Implementation for Young Women and Adolescents (PrIYA) Program. PrEP uptake among pregnant and postpartum women: Results from a large implementation program within routine maternal child health (MCH) clinics in Kenya.
        https://programme.aids2018.org/Abstract/Abstract/7484
        Date: 2018
        Date accessed: April 19, 2022
        (Accessed)
        • Joseph Davey D.L.
        • Baeten J.M.
        • Aldrovandi G.
        • et al.
        Emerging evidence from a systematic review of safety of pre-exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading?.
        J Int AIDS Soc. 2020; 23: e25426https://doi.org/10.1002/jia2.25426
        • Ibekwe E.
        • Haigh C.
        • Duncan F.
        • et al.
        Clinical outcomes of routine opt-out antenatal human immunodeficiency virus screening: a systematic review.
        J Clin Nurs. 2017; 26: 341-355https://doi.org/10.1111/jocn.13475
        • Killam W.P.
        • Tambatamba B.C.
        • Chintu N.
        • et al.
        Antiretroviral therapy in antenatal care to increase treatment initiation in HIV-infected pregnant women: a stepped-wedge evaluation.
        AIDS. 2010; 24: 85-91https://doi.org/10.1097/QAD.0b013e32833298be
        • Aliyu M.H.
        • Blevins M.
        • Audet C.M.
        • et al.
        Integrated prevention of mother-to-child HIV transmission services, antiretroviral therapy initiation, and maternal and infant retention in care in rural north-central Nigeria: a cluster-randomised controlled trial.
        Lancet HIV. 2016; 3: e202-e211https://doi.org/10.1016/S2352-3018(16)00018-7
      11. Differentiated service delivery for families - children, adolescents, and pregnant and breastfeeding women: A background review.
        (Available at:) (Accessed April 16, 2022)
        • Zerbe A.
        • Brittain K.
        • Phillips T.K.
        • et al.
        Community-based adherence clubs for postpartum women on antiretroviral therapy (ART) in Cape Town, South Africa: a pilot study.
        BMC Health Serv Res. 2020; 20: 621https://doi.org/10.1186/s12913-020-05470-5
        • Trafford Z.
        • Gomba Y.
        • Colvin C.J.
        • et al.
        Experiences of HIV-positive postpartum women and health workers involved with community-based antiretroviral therapy adherence clubs in Cape Town, South Africa | BMC Public Health | Full Text.
        (Available at:) (Accessed April 16, 2022)
        • Ioannidis J.P.
        • Abrams E.J.
        • Ammann A.
        • et al.
        Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml.
        J Infect Dis. 2001; 183: 539-545https://doi.org/10.1086/318530
        • Garcia P.M.
        • Kalish L.A.
        • Pitt J.
        • et al.
        Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.
        N Engl J Med. 1999; 341: 394-402https://doi.org/10.1056/NEJM199908053410602
        • Haberer J.E.
        • Bangsberg D.R.
        • Baeten J.M.
        • et al.
        Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm.
        AIDS. 2015; 29: 1277-1285https://doi.org/10.1097/QAD.0000000000000647
        • Hill L.M.
        • Maseko B.
        • Chagomerana M.
        • et al.
        HIV risk, risk perception, and PrEP interest among adolescent girls and young women in Lilongwe, Malawi: operationalizing the PrEP cascade.
        J Int AIDS Soc. 2020; 23https://doi.org/10.1002/jia2.25502
        • Seifert S.M.
        • Chen X.
        • Meditz A.L.
        • et al.
        Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.
        AIDS Res Hum Retroviruses. 2016; 32: 981-991https://doi.org/10.1089/AID.2016.0008
        • Cottrell M.L.
        • Yang K.H.
        • Prince H.M.A.
        • et al.
        A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.
        J Infect Dis. 2016; 214: 55-64https://doi.org/10.1093/infdis/jiw077
        • Patterson K.B.
        • Prince H.A.
        • Kraft E.
        • et al.
        Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission - PubMed.
        (Available at:) (Accessed April 19, 2022)
      12. Mweemba O, Zimba C, Chi BH, et al. Contextualising men’s role and participation in PMTCT programmes in Malawi and Zambia: A hegemonic masculinity perspective. Glob Public Health. Published online August 10, 2021:1-14. doi:10.1080/17441692.2021.1964559.

        • Golub S.A.
        PrEP Stigma: Implicit and Explicit Drivers of Disparity.
        Curr Hiv/aids Rep. 2018; 15: 190-197https://doi.org/10.1007/s11904-018-0385-0
        • Barker P.
        • Barron P.
        • Bhardwaj S.
        • et al.
        The role of quality improvement in achieving effective large-scale prevention of mother-to-child transmission of HIV in South Africa.
        AIDS. 2015; 29: S137-S143https://doi.org/10.1097/QAD.0000000000000718
        • Bhardwaj S.
        • Barron P.
        • Pillay Y.
        • et al.
        Elimination of mother-to-child transmission of HIV in South Africa: rapid scale-up using quality improvement.
        S Afr Med J. 2014; 104: 239-243https://doi.org/10.7196/samj.7605
        • Akama E.
        • Mburu M.
        • Mutegi E.
        • et al.
        Impact of a Rapid Results Initiative Approach on Improving Male Partner Involvement in Prevention of Mother to Child Transmission of HIV in Western Kenya.
        AIDS Behav. 2018; 22: 2956-2965https://doi.org/10.1007/s10461-018-2140-3
        • Rustagi A.S.
        • Gimbel S.
        • Nduati R.
        • et al.
        Implementation and Operational Research: Impact of a Systems Engineering Intervention on PMTCT Service Delivery in Côte d’Ivoire, Kenya, Mozambique: A Cluster Randomized Trial.
        J Acquir Immune Defic Syndr. 2016; 72: e68-e76https://doi.org/10.1097/QAI.0000000000001023
        • UNAIDS W.H.O.
        • UNICEF
        Key considerations for programming and prioritization. Going the ‘Last Mile’ to EMTCT: A road map for ending the HIV epidemic in children.
        (Available at:) (Accessed April 16, 2022)
        • Abrams E.J.
        • Myer L.
        • Rosenfield A.
        • et al.
        Prevention of mother-to-child transmission services as a gateway to family-based human immunodeficiency virus care and treatment in resource-limited settings: rationale and international experiences - American Journal of Obstetrics & Gynecology.
        (Available at:) (Accessed April 16, 2022)
        • Myer L.
        • Abrams E.J.
        • Zhang Y.
        • et al.
        Family matters: Co-enrollment of family members into care is associated with improved outcomes for HIV-infected women initiating antiretroviral therapy.
        J Acquir Immune Defic Syndr. 2014; 67: S243-S249https://doi.org/10.1097/QAI.0000000000000379
        • World Health Organization
        PMTCT strategic vision 2010-2015 : preventing mother-to-child transmission of HIV to reach the UNGASS and millennium Development Goals : moving towards the elimination of Paediatric HIV, December 2009.
        World Health Organization, 2010 (Available at:) (Accessed April 17, 2022)